SlateStone Wealth LLC Invests $205,000 in DexCom, Inc. (NASDAQ:DXCM)

SlateStone Wealth LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,630 shares of the medical device company’s stock, valued at approximately $205,000.

Several other large investors have also modified their holdings of DXCM. Blue Whale Capital LLP raised its holdings in DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after buying an additional 113,000 shares during the period. Motley Fool Asset Management LLC raised its holdings in DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock valued at $17,993,000 after buying an additional 171,150 shares during the period. Watts Gwilliam & Co. LLC purchased a new position in DexCom in the fourth quarter valued at approximately $3,334,000. Congress Asset Management Co. raised its holdings in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after buying an additional 1,332,522 shares during the period. Finally, Janney Montgomery Scott LLC raised its holdings in DexCom by 2,226.6% in the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock valued at $18,085,000 after buying an additional 222,548 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,657 shares of company stock worth $8,019,422. 0.30% of the stock is owned by insiders.

DexCom Stock Performance

DexCom stock opened at $71.35 on Tuesday. The company has a market cap of $27.88 billion, a PE ratio of 49.90, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a fifty day moving average price of $83.82 and a two-hundred day moving average price of $76.94. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on DXCM. Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Canaccord Genuity Group increased their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.